NHS Scotland to fund new therapies for AML, Arthritis and others

The Scottish Medicines Consortium has endorsed NHS funding for four therapies that  new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis. Pfizer’s Gemtuzumab ozogamicin was accepted for the treatment of acute myeloid leukaemia (AML), after being considered through the SMC’s Patient and Clinician Engagement (PACE) process. Current initial treatment for

Continue Reading

Pfizer treats first patient in trial for investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy

Pfizer has stated that they have begun their Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in patients with Duchenne muscular dystrophy (DMD). The first patient received an infusion of the mini-dystrophin gene, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University

Continue Reading

Balloon pulmonary angioplasty for lung disease patients to be funded by NHS in the UK

NHS England has stated it will be funding a pioneering procedure that will improve treatment outcomes for patients with a lung disease called Chronic Thromboembolic Pulmonary Hypertension (CTEPH). The condition involves chronic blood clots block blood flow in the arteries, raising pressure in the lung, which can cause heart failure and premature death. Patients with

Continue Reading